Clinical Trial Search

Primary: Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24. — 20.2; 43.7; 43.8; 43.8 Percentage of participants — p=<0.001

Primary: Change From Baseline to 24 Week Endpoint in Glycated Hemoglobin (HbA1c) — -1.00; -0.96; -0.98; -0.92 percentage HbA1c

Primary: Rate of Subjects With Serious Adverse Events and Medically Attended Adverse Events Until Day 56 After First Vaccination — 16.1; 14.2; 38.2; 42.2 percentage of…

Primary: Numbers of Treatment Related Side Effects (DLT = Reaction 3 or More) — 0; 0 side effects

Primary: Response to Induction Chemotherapy — 74; 11 Participants

Primary: Number of Drinks Per Week — 13.8; 12.0 standard alcohol drinks per week — p=0.82

Primary: Difference in Treatment vs. Placebo in Pill Capsule Completion Rates — 100; 0; 100 percentage of complete capsule studies

Primary: Mediastinal Nodal Clearance Rate — 27 participants

Primary: Number of Participants With Hepatic Adverse Events During the Conditioning Regimen Prior to Stem Cell Transplantation — 48; 30 participants

Primary: Incidence of New or Worsening Vertebral Fractures in Osteoporotic Subjects Treated With Denosumab Compared to Placebo — 3.6; 10.3; 7.2 Vertebral fractures — p=0.0001

Primary: Resting State Functional Activity Change From Baseline to 12 Weeks — 1.13; .79 z-score — p=<0.01

Primary: Patients With Circulating MCA Bubbles Present on MRI Who Had Signficant Clinical or Neurological Effects — 0 participants

Primary: Gross Weekly Purchasing of Fruits and Vegetables — 5.57; 1.79 $

Primary: Percent of Responders in the Last Four Weeks of the Double-Blind Treatment Period — 17.0; 17.8 percentage of subjects — p=0.9002

Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 24.2; 1.3 percentage of participants